Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 4, 2025
Subject: Update on Share Repurchase Programme
Novo Nordisk A/S is a leading global healthcare company headquartered in Denmark, employing approximately 72,000 people across 80 countries. The filing reports on the conclusion of a specific share repurchase sub-programme and provides an aggregate update on the company's broader capital return strategy.
Key Financial Metrics and Capital Allocation
This filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow).
- Sub-Programme Status: The programme initiated on November 11, 2024, concluded on February 3, 2025.
- Sub-Programme Volume: 4,599,494 B shares repurchased.
- Sub-Programme Value: DKK 3,136,204,070 (Target was DKK 3,136,206,122.30).
- Overall Programme Status (Started Feb 6, 2024):
- Total Shares Repurchased: 24,802,593 B shares.
- Total Value: DKK 19,999,997,948.
- Average Price: DKK 806.37 per B share.
- Target Cap: DKK 20 billion.
- Treasury Shares: 25,947,151 B shares held (0.6% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes and Recent Activity
The filing details transactions executed between January 27, 2025, and February 3, 2025, following a previous announcement on January 27. The average purchase price for these recent transactions ranged between DKK 598.38 and DKK 616.54, which is significantly lower than the overall programme average of DKK 806.37.
| Date | Shares Repurchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| Jan 27, 2025 | 93,500 | 613.35 | 57,348,068 |
| Jan 28, 2025 | 93,488 | 616.54 | 57,639,187 |
| Jan 29, 2025 | 94,000 | 615.03 | 57,812,465 |
| Jan 30, 2025 | 99,977 | 605.03 | 60,488,801 |
| Jan 31, 2025 | 100,000 | 611.79 | 61,179,203 |
| Feb 3, 2025 | 100,455 | 598.38 | 60,109,995 |
Guidance, Outlook, and Management Commentary
Programme Completion: The specific sub-programme authorized for DKK 3.1 billion has been fully executed. The broader 12-month programme (initiated February 6, 2024) has effectively reached its DKK 20 billion target, with the total repurchase value standing at DKK 19,999,997,948 as of February 4, 2025.
Operational Context: The filing reiterates the company's purpose to defeat serious chronic diseases, built upon its heritage in diabetes. It notes the company's global footprint with products marketed in around 170 countries.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond standard regulatory compliance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Key Facts for Investor Verification
- Capital Return Execution: Verify if the DKK 20 billion target for the 2024-2025 period is considered fully exhausted or if minor residual amounts remain for administrative closure.
- Share Price Volatility: Note the significant difference between the recent transaction prices (~DKK 600) and the overall programme average (DKK 806.37), indicating recent share price declines.
- Treasury Holdings: Confirm the impact of the 0.6% treasury share holding on earnings per share (EPS) calculations in future reports.
- Future Buybacks: Determine if management intends to announce a new share repurchase programme following the conclusion of the current DKK 20 billion authorization.